UK pharmaceutical company AstraZeneca could deliver the coronavirus vaccine as early as December, according to Bloomberg.
Vaccine candidate COVID-19 developed by AstraZeneca and University of Oxford is currently in phase three of trials in the US, UK and other countries to check if it is effective against the coronavirus that has already been transmitted. infected more than 48 million people and killed more than 1.2 people. million worldwide.
Our country is in a historic war against Coronavirus. Add your American changes Facebook or Twitter feed to stay up to date on news.
Results from the end-stage trials involving tens of thousands of participants are expected to be announced in the coming weeks. Once data is reported, regulators can approve it for widespread use if it is proven to be safe and effective.
“At the end of the day, we still don̵7;t know if the vaccine will work,” AstraZeneca’s CEO Pascal Soriot told Bloomberg.
“We hope that the large-scale vaccination will be able to start in January next year – possibly even December,” he told the store.
Soriot said the US Food and Drug Administration (FDA) may want to wait for results from the US trial, which was halted in September as other world trials continue, before Vaccine review and approval. AstraZeneca says it can deliver hundreds of millions of doses on a “roll-off” basis once the shot is approved.
AstraZeneca said last month its coronavirus vaccine was shown to induce an immune response in the elderly and the elderly.
Public health officials say reading data from end-stage trials is likely to happen before the end of that year, but said it’s likely that the coronavirus vaccine won’t be widely available to the public. them until May 2021.
THINGS YOU NEED TO KNOW ABOUT CORONAVIRUS RIGHT NOW
SCIENTS DISCOVER THE MAJOR CAUSES OF COVID-19 SYMPTOMS
COVID STRAIN MIGHT HINDER VACCINE EFFORT
AS MORE THAN 10,000 HAVE ATTENDED THE HALLOWEEN RAVE DEFYING CORONAVIRUS RULES
EXCELLENT AND SUPER LEVEL VERSION AND WHAT DO THEM MEAN FOR CORONAVIRUS?
CALIFORNIA FIRST SIMPLE FLUID AND IDENTIFYING IN A PATIENT